This company has been marked as potentially delisted and may not be actively trading. Ambrx Biopharma (AMAM) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock AMAM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Sunlands Technology (NYSE:STG) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comCormorant Global Healthcare Master Fund, LP's Net WorthAugust 31, 2024 | benzinga.com14 Day AMERIBOR Average Rate (^AMBRX)May 24, 2024 | finance.yahoo.comLatest News for Johnson & Johnson Stock (NYSE:JNJ)April 5, 2024 | benzinga.comAmbrx Biopharma Inc.: Ambrx Shareholders Approve Acquisition by Johnson & JohnsonMarch 7, 2024 | finanznachrichten.deJohnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash DealMarch 7, 2024 | markets.businessinsider.comAmbrx Shareholders Approve Acquisition by Johnson & JohnsonMarch 6, 2024 | globenewswire.comFmr LLC Sells 449,560 Shares of Ambrx Biopharma Inc. (NYSE:AMAM)March 5, 2024 | marketbeat.com70,000 Shares in Ambrx Biopharma Inc. (NYSE:AMAM) Bought by Monashee Investment Management LLCFebruary 25, 2024 | marketbeat.com3 Stocks to Buy That Are Up 200% or More in 2024February 23, 2024 | investorplace.comIs Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?February 20, 2024 | msn.comAmbrx Biopharma Inc. (NYSE:AMAM) Receives Consensus Rating of "Moderate Buy" from AnalystsFebruary 16, 2024 | marketbeat.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DOOR, CBAY, WISH, AMAMFebruary 12, 2024 | stockhouse.com47,433 Shares in Ambrx Biopharma Inc. (NYSE:AMAM) Acquired by Bank of New York Mellon CorpFebruary 12, 2024 | marketbeat.comAMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAMFebruary 10, 2024 | businesswire.comTD Asset Management Inc Grows Stock Holdings in Ambrx Biopharma Inc. (NYSE:AMAM)January 22, 2024 | marketbeat.comAmbrx Biopharma Inc. (NYSE:AMAM) Receives Average Recommendation of "Moderate Buy" from BrokeragesJanuary 22, 2024 | marketbeat.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AXNX, AMAM, HARPJanuary 20, 2024 | stockhouse.comRobert W. Baird Reiterates "Neutral" Rating for Ambrx Biopharma (NYSE:AMAM)January 16, 2024 | marketbeat.comJMP Securities Downgrades Ambrx Biopharma (AMAM)January 11, 2024 | msn.comAmbrx Biopharma (NYSE:AMAM) Rating Reiterated by JMP SecuritiesJanuary 10, 2024 | marketbeat.comAmbrx Biopharma just downgraded at JMP Securities, here's whyJanuary 10, 2024 | realmoney.thestreet.comAmbrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&JJanuary 9, 2024 | finance.yahoo.comAmbrx Biopharma (NYSE:AMAM) Stock Rating Reaffirmed by B. RileyJanuary 9, 2024 | marketbeat.comJ&J to buy cancer therapy developer Ambrx for $2 blnJanuary 8, 2024 | nasdaq.comAMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to ShareholdersJanuary 8, 2024 | tmcnet.comJohnson & Johnson: Biotech a shot in the arm for future growth? (AMAM)Johnson & Johnson is actively shifting its strategy towards biotechnology and antibody-drug conjugates, balancing current revenue protection with future growth.January 8, 2024 | marketbeat.comCrude Oil Falls Sharply; Ambrx Biopharma Shares Spike HigherJanuary 8, 2024 | markets.businessinsider.comWhy Is Ambrx Biopharma (AMAM) Stock Up 100% Today?January 8, 2024 | investorplace.comJohnson & Johnson to buy Ambrx Biopharma for $2 blnJanuary 8, 2024 | reuters.comAmbrx Announces Sale to Johnson & JohnsonJanuary 8, 2024 | finance.yahoo.comAmbrx Biopharma Inc. (NYSE:AMAM) Given Consensus Rating of "Moderate Buy" by AnalystsDecember 28, 2023 | marketbeat.comCantor Fitzgerald Reaffirms "Overweight" Rating for Ambrx Biopharma (NYSE:AMAM)December 21, 2023 | marketbeat.comAmbrix to Join NASDAQ Biotech IndexDecember 14, 2023 | msn.comAmbrx to be Added to the NASDAQ Biotechnology Index (NBI)December 14, 2023 | finance.yahoo.comCommodore Capital LP Has $52.26 Million Holdings in Ambrx Biopharma Inc. (NYSE:AMAM)December 10, 2023 | marketbeat.comOptimistic Outlook on Ambrx Biopharma’s Pipeline Justifies Buy RatingNovember 29, 2023 | markets.businessinsider.comAmbrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate CancerNovember 28, 2023 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Twist Bioscience (TWST) and Ambrx Biopharma (AMAM)November 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM) and Viridian Therapeutics (VRDN)November 14, 2023 | markets.businessinsider.comGoldman Sachs Keeps Their Hold Rating on Ambrx Biopharma (AMAM)November 14, 2023 | markets.businessinsider.comAmbrx Biopharma (AMAM) Price Target Increased by 8.17% to 25.79November 1, 2023 | msn.comCormorant Asset Management, LP Acquires New Stake in Ambrx Biopharma IncOctober 26, 2023 | finance.yahoo.comRBC Capital Maintains Ambrx Biopharma (AMAM) Outperform RecommendationOctober 24, 2023 | msn.comAmbrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO DataOctober 24, 2023 | seekingalpha.comAmbrx Biopharma: Potential With Recently Released Prostate Cancer DataOctober 23, 2023 | seekingalpha.comAnalyst Ratings for Ambrx BiopharmaOctober 23, 2023 | markets.businessinsider.comAmbrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved TreatmentsOctober 23, 2023 | finance.yahoo.comCancer Focused Ambrx Biopharma Stock Trading Lower Today - Here's WhyOctober 16, 2023 | benzinga.comAmbrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO CongressOctober 16, 2023 | finance.yahoo.com Get Ambrx Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter. Email Address AMAM Media Mentions By Week AMAM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMAM News Sentiment▼0.000.90▲Average Medical News Sentiment AMAM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMAM Articles This Week▼00▲AMAM Articles Average Week Get Ambrx Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRME News Today IKT News Today PLX News Today IZTC News Today ACHL News Today ZIVO News Today BLUE News Today CYTH News Today ALVR News Today NKGN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:AMAM) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ambrx Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ambrx Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
